Safety of chronic low-dose capecitabine as maintenance therapy in gastrointestinal cancers

Gastrointestinal Cancer Research

Volumn 3, Issue 4, 2010, Pages 134-140

  Sun, Jun F ^a   Wu, Rebekah R ^a   Norris, Craig ^b   Noone, Anne Michelle ^c   Amankwa Sakyi, Margaret ^c   Slack, Rebecca ^c   Marshall, John L ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLISTER; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; MEAN CORPUSCULAR VOLUME; MUCOSA INFLAMMATION; NATIONAL HEALTH ORGANIZATION; NAUSEA; NEUTROPENIA; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN ABRASION; SKIN BLEEDING; SKIN DISEASE; SKIN EDEMA; SKIN PAIN; TREATMENT OUTCOME;

EID: 77958099612     PISSN: 19347820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Pfeiffer P, Mortensen JP, Bjerregaard B, et al: Patient preference for oral or intravenous chemotherapy: a randomized cross-over trial comparing capecitabine and Nordic fluoro uracil/leucovorin in patients with colorectal cancer. Eur J Cancer 42:2738-2743, 2006
2. Petrioli R, Paolelli L, Marsili S, et al: FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. Oncology 70:345-350, 2006
3. Buter J, Sinnige HA, Sleijfer DT, et al: 5-Fluoro-uracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer: effects of maintenance therapy on remission duration. Cancer 75:1072-1076, 1995
4. Satoh S, Kawashima K, Matsumoto S, et al: Retrospective evaluation of sequential outpatient chemotherapy for advanced gastric cancer. Chemotherapy 53:226-232, 2007
5. Bramhall SR, Hallissey MT, Whiting J, et al: Mari-mastat as maintenance therapy for patients with advanced gastric cancer: a randomized trial. Br J Cancer 86:1864-1870, 2002
6. Kawano K, Inokuchi T, Fujihara T, et al: Usefulness of 5-FU high-dose continuous therapy at home in patients with recurrent gastric and colon cancer. Gan To Kagaku Ryoho 21 (Suppl):427-432, 1994 Japanese
7. Brunner TB, Tinkl D, Grabenbauer GG, et al: Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma: a retrospective analysis of prospectively recruited patients. Strahlenther Onkol 182:210-215, 2006
8. Iannitti D, Dipetrillo T, Akerman P, et al: Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol 28: 570-575, 2005
9. Malet-Martino M, Martino R: Clinical studies of three oral prodrugs of 5-fluorouracil (cape -citabine, UFT, S-1): a review. The Oncologist 7:288-323, 2002
10. Maindrault-Goebel F, Lledo G, Chibaudel B, et al: OPTIMOX2, a large, randomized phase II study of maintenance therapy or chemotherapy- free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MCRC). A GERCOR study. 2006 ASCO Annual meeting Proceedings. J Clin Oncol 24:18S, 2006 (abstr 3504)
11. Kato H, Ichinose Y, Ohta M, et al: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350:1713-1721, 2004
12. Miyashiro I, Furukawa H, Sasako M, et al: Gastric Cancer Surgical Study Group, Japan Clinical Oncology Group. No survival benefit with adjuvant chemotherapy for serosa-positive gastric cancer: Randomized trial of adjuvant chemotherapy with cisplatin followed by oral fluorouracil in serosa-positive gastric cancer. Japan Clinical Oncology Group 9206-2. 2005 ASCO Gastrointestinal Cancers Symposium. (abstr 4)
13. Cassidy J, Twelves C, Van Cutsem E, et al: Cape-citabine Colorectal Cancer Study Group. Firstline oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13:566-575, 2002
14. Van Cutsem E, Twelves C, Cassidy J, et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097-4106, 2001
15. Marshall J: Optimum use of biologics and role of maintenance therapy in colon cancer. Semin Oncol 33(suppl 11):S33-S35, 2006
16. Verweij J: Rational design of new tumor activated cytotoxic agents. Oncology 57(suppl):9-15, 1999
17. Van Cutsem E, Findlay M, Osterwalder B, et al: Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 18:1337-1345, 2000
18. Ratain M: Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 16:2297-2298, 1998
19. de Jong FA, Mathijssen RHJ, Zie R, et al: Flatfixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res 10:4068-4071, 2004
20. Miller AA, Rosner GL, Egorin MJ, et al: Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res 10:8325-8331, 2004
21. Gurney HP, Ackland S, Gebski V, et al: Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol 16:2299-2304, 1998
22. Wenzel C, Mader RM, Steger GG, et al: Cape-citabine treatment results in increased mean corpuscular volume of red blood cells in patients with advanced solid malignancies. Anti-Cancer Drugs 14:119-123, 2003
23. Karvellas CJ, Sawyer M, Hamilton M, et al: Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer. Am J Clin Onc 27:364-368, 2004
24. Walko CM, Lindley C: Capecitabine: a review. Clin Ther 27:23-44, 2005